Key Highlights

  • Twist Bioscience shares closed at $184.03 today, up 16.11%, reaching fresh 52-week highs.
  • The rally extends a multi-week move driven by the company's September announcement of joining Eli Lilly's TuneLab platform as a preferred antibody characterization data provider.
  • The stock briefly pulled back to profit-taking after a Form 144 filing showed the CEO's planned sale of 1,688 shares, but sentiment has since turned bullish again.
  • The rally also reflects strong underlying fundamentals, with second-quarter Revenue of $118.4 million and raised full-year guidance.

Lilly Partnership Continues to Drive Shares Higher

Twist Bioscience (NASDAQ:TWST) shares closed sharply higher today, extending a multi-week rally driven by its September announcement of joining Eli Lilly's (NYSE:LLY) TuneLab platform as a preferred antibody characterization data provider. Investors see the partnership as validating Twist's AI-enabled antibody discovery capabilities, a milestone that has kept the stock in favor even after a brief pullback tied to insider selling earlier in the month.

Strong Fundamentals Underpin the Rally

The rally also comes against a backdrop of strong underlying fundamentals, with second-quarter revenue of $118.4 million and raised full-year guidance reported in early August, alongside a broader resurgence in investor interest across the life sciences tools sector amid AI-driven drug discovery optimism. A brief dip on September 23 tied to profit-taking followed a Form 144 filing showing the company's CEO planned to sell 1,688 shares, but sentiment has since turned bullish again as the stock pushes to fresh 52-week highs.

A Leading Synthetic Biology and Genomics Platform

Twist Bioscience is a synthetic biology and genomics company headquartered in South San Francisco, California, that manufactures and sells synthetic DNA products, including synthetic genes, gene fragments, oligo pools, next-generation sequencing tools and antibody libraries used in drug discovery and development. The company maintains strategic partnerships across the globe, including collaborations with Boehringer Ingelheim and Centogene, and continues to drive innovation in the engineering of biology for customers spanning biopharmaceutical, academic, industrial and diagnostics sectors.